Skip to content

Clinical Study of Intravenous Magnesium Sulfate Administration During Thyroidectomy with Intraoperative Recurrent Laryngeal Nerve Monitoring Under General Anesthesia.

Clinical Study of Intravenous Magnesium Sulfate Administration During Thyroidectomy with Intraoperative Recurrent Laryngeal Nerve Monitoring Under General Anesthesia.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117885
Enrollment
Unknown
Registered
2026-01-29
Start date
2025-07-31
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroidectomy with Intraoperative Recurrent Laryngeal Nerve Monitoring Under General Anesthesia

Interventions

Control group:5% glucose injection, intravenous infusion: Loading volume 0.4ml/kg (10 minutes before anesthesia induction), maintenance volume 0.2ml/kg/h (until the end of the operation)
Trial group:Dilute 50% magnesium sulfate injection to 10% concentration for intravenous infusion: loading volume 0.4ml/kg (10 minutes before anesthesia induction), maintenance volume 0.2ml/kg/h (until

Sponsors

Fifth Affiliated Hospital, Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Voluntarily signed informed consent form; 2.Aged between 18 and 60 years; 3.No gender restriction; 4.ASA physical status classification I-II; 5.Patients undergoing thyroidectomy with intraoperative recurrent laryngeal nerve monitoring under general anesthesia.

Exclusion criteria

Exclusion criteria: 1.Preoperative systolic blood pressure 180 mmHg or diastolic blood pressure >90 mmHg; 3.Renal dysfunction (glomerular filtration rate [GFR] 97 µmol/L, blood urea nitrogen [BUN] >8 mmol/L); 4.History of neuromuscular disorders; 5.History of cardiac ischemia or conduction block; 6.Pregnancy or lactation; 7.Chronic calcium channel blocker therapy; 8.History of hypersensitivity to magnesium compounds or general anesthetic agents; 9.Electrolyte abnormalities (hypokalemia, hypocalcemia, hypermagnesemia); 10.Random blood glucose >11.1 mmol/L; 11.Body mass index (BMI) 30 kg/m²; 12.Anticipated difficult mask ventilation or intubation (limited mouth opening, restricted head/neck mobility, short thyromental distance, or history of difficult intubation).

Design outcomes

Primary

MeasureTime frame
The duration of action of muscle relaxants;

Secondary

MeasureTime frame
Incidence of adverse events;The incidence of glottic activity, diaphragmatic movement and choking cough during tracheal intubation;

Countries

China

Contacts

Public ContactYang Simin

Fifth Affiliated Hospital, Sun Yat-Sen University

simin22@qq.com+86 756 2528354

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026